Sign up
Pharma Capital

Actinogen moves to next stage of Alzheimer's treatment trials

Biotech Actinogen has signed 174 patients for its trial of the drug Xanamem, which may offer a novel new treatment of Alzheimer's disease.

Managing Director Dr Bill Ketelbey says the drug, which treats increased cortisol levels that may decrease cognitive ability, could be "an enormously valuable asset" even though it only treats, rather then cures Alzheimer's.

 

View full ACW profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.